Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Free Cash Flow (2018 - 2025)

Historic Free Cash Flow for Neurogene (NGNE) over the last 6 years, with Q3 2025 value amounting to -$19.6 million.

  • Neurogene's Free Cash Flow fell 2473.0% to -$19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$78.4 million, marking a year-over-year decrease of 1064.07%. This contributed to the annual value of -$71.4 million for FY2024, which is 3801.09% down from last year.
  • Neurogene's Free Cash Flow amounted to -$19.6 million in Q3 2025, which was down 2473.0% from -$19.6 million recorded in Q2 2025.
  • Neurogene's 5-year Free Cash Flow high stood at -$9.4 million for Q2 2023, and its period low was -$21.8 million during Q1 2024.
  • Over the past 3 years, Neurogene's median Free Cash Flow value was -$17.0 million (recorded in 2023), while the average stood at -$16.7 million.
  • As far as peak fluctuations go, Neurogene's Free Cash Flow plummeted by 7295.89% in 2024, and later soared by 119.5% in 2025.
  • Quarter analysis of 3 years shows Neurogene's Free Cash Flow stood at -$17.0 million in 2023, then dropped by 3.23% to -$17.6 million in 2024, then decreased by 11.56% to -$19.6 million in 2025.
  • Its last three reported values are -$19.6 million in Q3 2025, -$19.6 million for Q2 2025, and -$21.6 million during Q1 2025.